GSK invests $300,000 to help launch the Pharmacy Innovation in Immunization Research Collaborative (PIIRC) at the University of Waterloo School of Pharmacy Français
MISSISSAUGA, ON, June 6, 2025 /CNW/ - GSK is proud to announce a $300,000 investment in the Pharmacy Innovation in Immunization Research Collaborative (PIIRC), a new national initiative led by the School of Pharmacy at the University of Waterloo. This groundbreaking initiative reflects a shared commitment to expanding the role of pharmacy in Canada's immunization landscape and improving equitable access to vaccines across the country.
Immunization has never been more critical. The COVID-19 pandemic underscored the life-saving power of vaccines and demonstrated the essential role that pharmacists and pharmacies play in public health. Pharmacy teams have administered more than 20 million COVID-19 vaccines in Canada alone. Yet, there remains untapped potential to leverage the country's 11,000+ pharmacies as accessible, community-based hubs for broader immunization services. PIIRC aims to close that gap.
Launched by the largest clinical pharmacy practice research group in Canada, PIIRC serves as a catalyst for innovation by supporting interdisciplinary research and real-world evidence generation focused on improving vaccine access, delivery and education. The initiative brings together researchers from the University of Waterloo, national and international collaborators, policymakers and stakeholders across healthcare and industry to advance pharmacy-based immunization strategies.
"As a global leader in vaccines, we believe in harnessing science and partnerships to tackle the world's most pressing health challenges," said Michelle Horn, Country Medical Director, GSK Canada. "Through our founding partnership with PIIRC, we are investing not only in research, but in the future of vaccine delivery in Canada—one that is more accessible, equitable, and community-centred."
Transforming Immunization Through Pharmacy Innovation
The objective of PIIRC is to re-imagine the role of pharmacy in immunization—from vaccine administration to health education, monitoring, and system design. Areas of research will include:
Expanding the role of pharmacists and pharmacy technicians as vaccine educators, facilitators, and immunizers
Overcoming barriers to access, especially among rural residents, older adults, immunocompromised individuals, and other underserved populations
Leveraging digital health tools and technology to support clinical decision-making and personalized outreach
Countering vaccine misinformation through evidence-based communication strategies and resources for healthcare providers
Conducting economic analyses to examine the cost-effectiveness and public health value of pharmacy-based vaccine services
Implementing science methodologies to ensure successful and scalable solutions across regions and populations
This work will be supported by the School's extensive expertise in pharmacy practice research, health systems design, health economics, public policy, behavioural science, and communication strategies.
"As a leader in clinical pharmacy practice research and community pharmacy innovation, the University of Waterloo's School of Pharmacy continues to push boundaries," said Andrea Edginton, Hallman Director, School of Pharmacy at the University of Waterloo. "PIIRC is a natural evolution of our work in immunization, and GSK's partnership will accelerate breakthroughs that improve public health both in Canada and globally."
Impact Beyond the Lab
In addition to funding innovative research, GSK's investment will also:
Provide funding to support new interdisciplinary projects with direct policy and practice implications
Train the next generation of immunization researchers, including PharmD students, graduate students and postdoctoral fellows
Facilitate enhanced access to real-world pharmacy data to monitor vaccine uptake and identify areas for intervention
Establish a network of community pharmacies engaged in research, data collection and pilot projects
Enable regular knowledge translation activities to ensure research is informed by and disseminated to industry, government and community stakeholders
Support the creation of an Advisory Board that includes voices from pharmaceutical and insurance companies, regulators, pharmacy associations and the public
Strategic Alignment with Public Health and Policy
This investment directly supports the Ontario Life Sciences Strategy by demonstrating private sector leadership in supporting community-based immunization services. By investing in evidence that shows how pharmacy can help achieve broader public health goals—including for future vaccine program rollouts such as RSV—GSK is playing a critical role in advancing both healthcare outcomes and policy development.
"Our support for PIIRC is not just about generating data; it's about making a meaningful contribution to the future of healthcare," added Michelle Horn, Country Medical Director, GSK Canada. "We're proud to stand alongside the University of Waterloo School of Pharmacy in driving innovative, patient-centred immunization strategies that reflect our mission to get ahead of disease together and our commitment to doing what's right for communities and for public health."
Why Waterloo and Why Now?
The University of Waterloo's collaborative ethos, track record of external partnerships and commitment to impact make it an ideal home for PIIRC. The University creates substantial opportunities for high-impact partnerships that bridge the gap between research and application.
PIIRC helps shape policy and guides decision-making with timely, actionable evidence that reflects the realities of patients, pharmacists and public health professionals. GSK's early and decisive investment solidifies its reputation as a forward-thinking leader in the pharmacy space and a partner of choice in advancing vaccine innovation.
About the University of Waterloo School of Pharmacy
The School of Pharmacy at the University of Waterloo is home to Canada's largest clinical pharmacy practice research group and is at the forefront of pharmacy innovation. Through interdisciplinary research and industry collaboration, the School is advancing pharmacy's role in improving health systems and patient outcomes.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at www.ca.gsk.com/en-ca.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.
SOURCE GlaxoSmithKline Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
a day ago
- Winnipeg Free Press
Got the sniffles? Here's what to know about summer colds, COVID-19 and more
Summer heat, outdoor fun … and cold and flu symptoms? The three may not go together in many people's minds: partly owing to common myths about germs and partly because many viruses really do have lower activity levels in the summer. But it is possible to get the sniffles — or worse — in the summer. Federal data released Friday, for example, shows COVID-19 is trending up in many parts of the country, with emergency department visits up among people of all ages. Here's what to know about summer viruses. How much are colds and flu circulating right now? The number of people seeking medical care for three key illnesses — COVID-19, flu and respiratory syncytial virus, or RSV — is currently low, according to data from the Centers for Disease Control and Prevention. Flu is trending down and RSV was steady this week. But COVID-19 is trending up in many mid-Atlantic, southeast, Southern and West Coast states. The expectation is that COVID-19 will eventually settle into a winter seasonal pattern like other coronaviruses, but the past few years have brought a late summer surge, said Dr. Dean Blumberg, chief of pediatric infectious diseases at University of California Davis Children's Hospital. Other viruses circulating this time of year include the one that causes 'hand, foot and mouth' disease — which has symptoms similar to a cold, plus sores and rashes — and norovirus, sometimes called the stomach flu. Do viruses spread less in the summer? Many viruses circulate seasonally, picking up as the weather cools in the fall and winter. So it's true that fewer people get stuffy noses and coughs in the summer — but cold weather itself does not cause colds. It's not just about seasonality. The other factor is our behavior, experts say. Nice weather means people are opening windows and gathering outside where it's harder for germs to spread. But respiratory viruses are still around. When the weather gets too hot and everyone heads inside for the air conditioning, doctors say they start seeing more sickness. In places where it gets really hot for a long time, summer can be cold season in its own right. 'I grew up on the East Coast and everybody gets sick in the winter,' said Dr. Frank LoVecchio, an emergency room doctor and Arizona State University researcher. 'A lot of people get sick in the summer here. Why is that? Because you spend more time indoors.' Should you get another COVID-19 booster now? For people who are otherwise healthy, timing is a key consideration to getting any vaccine. You want to get it a few weeks before that big trip or wedding, if that's the reason for getting boosted, doctors say. But, for most people, it may be worth waiting until the fall in anticipation of winter cases of COVID-19 really tick up. 'You want to be fully protected at the time that it's most important for you,' said Dr. Costi Sifri, of the University of Virginia Health System. People at higher risk of complications should always talk with their doctor about what is best for them, Sifri added. Older adults and those with weak immune systems may need more boosters than others, he said. Are more younger kids getting sick with COVID-19? Last week, the CDC noted emergency room visits among children younger than 4 were rising. That makes sense, Blumberg said, because many young kids are getting it for the first time or are unvaccinated. Health Secretary Robert F. Kennedy Jr. said in May that the shots would no longer be recommended for healthy kids, a decision that health experts have said lacks scientific basis. The American Academy of Pediatrics still endorses COVID-19 shots for children older than 6 months. Wednesdays What's next in arts, life and pop culture. How else can I lower my risk? The same things that help prevent colds, flu and COVID any other time of the year work in the summer, doctors say. Spend time outside when you can, wash your hands, wear a mask. And if you're sick, stay home. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Edmonton Journal
2 days ago
- Edmonton Journal
Saturday's letters: Is UCP against Albertans with disabilities?
Article content As a parent of an adult with Down syndrome, we are very familiar with AISH. My daughter works part-time, volunteers and participates actively in art and sports programs. She is also an AISH recipient. AISH is essential for her financial needs, dental needs and diabetic needs. What AISH doesn't cover, family does. Article content The $200 Canada Disability Benefit is a very nice supplement to the existing AISH income. It will help with expenses which AISH doesn't cover. This federal government gesture is meant to supplement, not take away from any existing provincial programs for persons with disabilities. Article content Article content Article content Article content Kudos to Keith Gerein and his description of crowdfunding, especially his note '… it's nice to see an innovative attempt to have the public directly contribute to the revitalization without relying on corporate or government millions. And if it works, perhaps that can be a model to re-energize other meaningful properties in the city.' Article content Article content I heartily agree, especially now that the province has reopened the possibility of salvaging the old provincial museum and is accepting proposals into September. If a crowdfunding opportunity arose to help save the old RAM, I, for one, would gladly contribute. I am sure many others would too. Perhaps it's not too late to save that beautiful, old building. Article content Pat Holt, Edmonton Article content Our previous premier, Jason Kenney, valued Albertans' health and lives sufficiently that, in the fall of 2021, his UCP government actually provided vaccine-hesitant Albertans with a $100 debit card to undertake one or even two COVID-19 vaccinations, typically (and conveniently) at their neighborhood pharmacy. Article content In striking contrast and just four years later, it appears that our current premier, Danielle Smith, places much less value on Albertans' health and lives. Her UCP government plans, in the fall of 2025, both to charge us a significant price (likely more than $100 each) for our COVID-19 vaccinations and to require that those of us who find this affordable to book our COVID-19 vaccination appointments, in advance, at a small number of often-inconveniently-located public health clinics.
Cision Canada
2 days ago
- Cision Canada
CABHI launches AgeTech Insights to shape the future of aging Français
TORONTO, Aug. 1, 2025 /CNW/ - The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, launched AgeTech Insights at the Global Dementia Research + Innovation Showcase, its flagship event during the Alzheimer's Association International Conference (AAIC) 2025. The novel hub will help drive Canadian innovation by mobilizing knowledge and sharing market intelligence in the aging and brain health sector. "AgeTech Insights shares critical knowledge with entrepreneurs, investors, innovators, ecosystem builders, and policymakers to gain a deeper understanding of the current technology trends among older persons in Canada and around the world," said Dr. Allison Sekuler, President and Chief Scientist at CABHI and the Baycrest Academy for Research and Education. "These insights will ensure innovations are designed to meet the needs of older persons while advancing economic growth, in line with demographic trends as they shift in our country." As an innovation catalyst, CABHI supports innovators—scientists, researchers, clinicians, startup companies, and healthcare organizations—at all stages of their innovation journey. From helping early-career scientists and researchers join the innovation ecosystem through the CABHI Science Collaborative, to supporting innovators develop, test, and refine their solutions through the NextGen Support Package and Ignite, all the way to helping AgeTech companies with growth and scale through Fuel. AgeTech Insights will complement these efforts by identifying gaps, highlighting trends, and informing the development of age-inclusive solutions. Canada is facing a historic demographic shift with nearly one in five Canadians over the age of 65, and that number is set to rise dramatically. This change is reshaping the country's economy and health systems, creating an urgent demand for innovation in aging and brain health. CABHI's AgeTech Insights is designed to help meet this demand. The announcement took place during the Global Dementia Research + Innovation Showcase, attended by over 300 guests, including Michelle Cooper, Parliamentary Assistant to the Minister of Finance, Member of the Standing Committee on Public Accounts, and Member of Provincial Parliament for Eglinton—Lawrence, and Laura Smith, First Vice-Chair, Standing Committee on Procedure and House Affairs, Parliamentary Assistant to the Minister of Municipal Affairs and Housing (Housing), Member of the Standing Committee on Government, and Member of Provincial Parliament for Thornhill. AgeTech Insights will serve as a national and global knowledge hub to inform scientists, researchers, innovators, entrepreneurs, and policymakers on the needs of older persons while unlocking opportunities in the rapidly growing AgeTech market. "Ontario-made research is driving our economy and improving lives across the province," said Nolan Quinn, Minister of Colleges, Universities, Research and Excellence. "Our government is proud to support the Centre of Aging + Brain Health and commend their newest hub, AgeTech Insights, which will further advance discoveries at postsecondary and research institutions, leading to better, stronger brain health care for seniors in Ontario." AgeTech Insights launched with its first market intelligence report, offering insights into technology use in Canadians aged 50+, shedding light on barriers and enablers, and informing innovators how to apply this intelligence to their work. CABHI will share insights from Canadians aged 50+ through reports and knowledge products in collaboration with national and international ecosystem partners. By tracking, analyzing, and disseminating global trends, AgeTech Insights will influence innovation design, uptake, and policy in Canada, positioning the country as a global AgeTech leader. Learn more about the first AgeTech Insights Report and other knowledge products online on CABHI's website. About the Centre for Aging + Brain Health Innovation: The Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, was established in 2015 to support researchers, clinicians, and innovators, as they develop and adopt transformative innovations that improve the lives of older persons, including those impacted by dementia. CABHI is a unique collaboration of healthcare, science, industry, not-for-profit, and government partners. Through its funding programs and tailored acceleration services, including access to diverse end-user groups, CABHI advances transformative aging and brain health innovations across Canada and the world. For more information, visit: About Baycrest: At Baycrest, our vision is a world where every older person lives with purpose, fulfilment and dignity. Baycrest is a global leader in aging and brain health innovation, with over 105 years of expertise in seniors' care and cutting-edge research. Baycrest has been Designated with Exemplary Status by Accreditation Canada, and drives industry-leading care and safety outcomes. As the home of the Centre for Aging + Brain Health Innovation (CABHI) powered by Baycrest, the Baycrest Academy for Research and Education (BARE) and the Canadian Consortium on Neurodegeneration in Aging, Baycrest is at the forefront of dementia research. Affiliated with the University of Toronto, Baycrest's training programs shape the future of care globally, while Baycrest Global Solutions extends its expertise to senior living and healthcare internationally. For more information, visit:
